Calmark receives order from India
Calmark Sweden AB (publ) announces today that an order for 50 instruments and 2,000 test cassettes relating to the Calmark Neo-Bilirubin product has been received from the Company's distributor in India, r2 Diagnostics. The registration process in India for the products is ongoing and is anticipated to be completed shortly.
Today's order comprises 50 instruments with associated test cassettes to be dispatched to end customers in selected children’s hospitals in India according to a release plan. The order will be delivered as soon as the registration process is completed.
“I am very pleased that things are under way in the vast and important market of India. The fact that this order arrives before the registration process is fully completed shows that the distributor is committed and really eager to shorten the time-to-delivery for customers,” says Magdalena Tharaldsen, Calmark’s Director International Business Development. “Approximately 25 million children are born every year in India, and the market for bilirubin blood tests exceeds 7.5 million tests.”
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 19-08-2022 08:39 CET.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: